Want to see JP:4591 full AI Analyst Report?
4591 Stock Chart & Stats
¥75.00
¥23.00(27.71%)
At close: 4:00 PM EST
¥75.00
¥23.00(27.71%)
Day’s Range― - ―
52-Week Range¥57.00 - ¥120.00
Previous CloseN/A
Volume38.87M
Average Volume (3M)785.42K
Market Cap
¥4.53B
Enterprise Value¥610.54
Total Cash (Recent Filing)¥2.78B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-22.85
Shares Outstanding56,572,640
10 Day Avg. Volume488,180
30 Day Avg. Volume785,420
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)1.54
Price to Sales (P/S)1456.29
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free, Net-cash Balance SheetZero debt and a net-cash position reduce insolvency and refinancing pressure, giving Ribomic more flexibility to fund research while preserving optionality through a difficult development period. The meaningful equity base also provides a stronger cushion than leveraged biotech peers.
Revenue ReboundRevenue rebounded in the latest 2026 annual period and the reported growth rate is exceptionally high from a very low base. If the improvement persists, it could broaden funding capacity and demonstrate progress beyond a purely pre-revenue profile, although scale remains limited.
Potential Cash-burn ImprovementThe cash-flow review notes periods in which cash burn improved versus prior years. While this has not changed the overall negative pattern, sustained efficiency gains could extend the runway of existing resources and reduce the pace at which equity funding is consumed.
Bears Say
Persistent Deep LossesPersistent operating and net losses show that the current business remains far from self-sustaining, despite the latest revenue rebound. Extremely negative margins indicate that sales are still too small relative to expenses, making profitability dependent on substantial future improvement.
Ongoing Cash BurnConsistently negative operating and free cash flow means Ribomic is consuming cash rather than funding operations internally. This weakens financial resilience, increases reliance on existing cash or equity funding, and could constrain the pace of research investment if losses persist.
Eroding Capital BaseA declining equity base indicates that continuing losses are steadily consuming shareholder capital even though the company has no debt. If this trajectory continues, Ribomic will have less balance-sheet capacity to absorb setbacks or finance development without raising additional equity.
Ribomic, Inc. News
4591 FAQ
What was Ribomic, Inc.’s price range in the past 12 months?
Ribomic, Inc. lowest stock price was ¥57.00 and its highest was ¥120.00 in the past 12 months.
What is Ribomic, Inc.’s market cap?
Ribomic, Inc.’s market cap is ¥4.53B.
When is Ribomic, Inc.’s upcoming earnings report date?
Ribomic, Inc.’s upcoming earnings report date is Nov 17, 2026 which is in 57 days.
How were Ribomic, Inc.’s earnings last quarter?
Ribomic, Inc. released its earnings results on Aug 13, 2026. The company reported -¥4.87 earnings per share for the quarter.
Is Ribomic, Inc. overvalued?
According to Wall Street analysts Ribomic, Inc.’s price is currently Overvalued.
Does Ribomic, Inc. pay dividends?
Ribomic, Inc. does not currently pay dividends.
What is Ribomic, Inc.’s EPS estimate?
Ribomic, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ribomic, Inc. have?
Ribomic, Inc. has 56,572,640 shares outstanding.
What happened to Ribomic, Inc.’s price movement after its last earnings report?
Ribomic, Inc. reported an EPS of -¥4.87 in its last earnings report. Following the earnings report the stock price went down -1.299%.
Which hedge fund is a major shareholder of Ribomic, Inc.?
Currently, no hedge funds are holding shares in JP:4591
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ribomic, Inc.
Ribomic Inc. is a Japanese biopharmaceutical company dedicated to identifying and advancing medicinal compounds. The firm employs RNA aptamers in its drug development efforts, targeting various significant health issues such as wet age-related macular degeneration, achondroplasia, pulmonary arterial hypertension, proliferative vitreoretinopathy, heart failure, osteoarthritis, and asthma. Furthermore, Ribomic manufactures specialized separating agents used for the affinity purification of human IgG and Fc-fusion proteins. Established in 2003, the company's main operations are based in Tokyo, Japan.